中医中药

小儿上呼吸道感染治疗中应用喜炎平注射液的临床价值

马琰

[文章下载]

【摘要】  【摘要】目的 分析小儿上呼吸道感染治疗中应用喜炎平注射液的临床价值。方法 选取2016年3月至2019年12月本院收治的102例小儿上呼吸道感染患儿,根据不同治疗方案将其分成两组各51例,对照组采用利巴韦林注射液[10 mg/(kg•d),配以5%葡萄糖溶液250 mL,静脉滴注,qd]治疗,观察组在此基础上采用喜炎平注射液[5 mg/(kg•d),配以5%葡萄糖溶液250 mL,静脉滴注,qd]治疗,7 d后比较两组患儿的症状消失时间和临床疗效,统计不良反应发生情况。

【关键字】  上呼吸道感染,喜炎平,安全性

中图分类号:文献标识码:文章编号:

[Abstract]Objective To analyze the clinical value of Xiyanping injection in the treatment of upper respiratory tract infection in children. Methods A total of 102 children with upper respiratory tract infection admitted to our hospital from March 2016 to December 2019 were enrolled in this study. According to different treatment protocols, 51 patients were divided into two groups. The control group was treated with ribavirin injection [10 mg/(kg•d), with 250 mL of 5% glucose solution, intravenous drip, qd] treatment, the observation group on this basis using Xiyanping injection [5 mg/(kg•d), with 5% glucose solution 250 mL Intravenous infusion, qd] treatment, 7 days after the two groups of children with symptom disappearance time and clinical efficacy, statistical adverse reactions occurred. Results The disappearance time, disappearance time of cough and disappearance of nasal obstruction were significantly shorter in the observation group than in the control group (P<0.05). The effective rate of treatment in the observation group (96.08%) was significantly higher than that in the control group (80.39%). P<0.05); the incidence of adverse reactions in the observation group (5.88%), and the control group (9.80%), there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion The application of Xiyanping injection in the treatment of upper respiratory tract infection in children can effectively shorten the disappearance of symptoms in children, improve clinical efficacy, and be safe and reliable.

上呼吸道感染是儿科高发呼吸道疾病类型之一,主要由病毒、支原体、细菌感染引发所致,具有发病率高、起病急、进展迅速的特点[1-2]。临床中儿科上呼吸道感染发生率约为28%,患者主要表现为咳嗽、鼻塞流涕、发热、恶心呕吐、厌食等症状,多采用抗病毒疗法治疗患儿[3-4]。由于抗病毒类药物具有明显的副作用,部分患儿用药后会产生耐药性,影响小儿身心健康,因此有必要研究科学的治疗路径[5-6]。为了探讨更加高效、合理的治疗方案,本文就小儿上呼吸道感染治疗中应用喜炎平注射液的临床价值展开了下述分析。 1 资料与方法 1.1 一般资料:选取本院2016年3月至2019年12月收治的小儿上呼吸道感染患儿102例。纳入标准:①符合上呼吸道感染的诊断标准[7],伴有流涕、咳嗽、发热、声音嘶哑等症状,体温>38.0 ℃,血常规提示外周血白细胞计数正常;②病程<5 d;③患儿家属同意配合研究。排除标准:①器质性功能障碍;②药物过敏;③造血系统疾病;④免疫系统疾病;⑤临床资料缺失。根据不同治疗方案将其分成两组,每组51例,观察组男27例,女24例;年龄1~8岁,平均(3.28±0.39)岁。对照组男26例,女25例;年龄1~7岁,平均(3.42±0.41)岁。患儿家属均具知情权,组间基线数据对比均衡性良好。 1.2 方法:给予全部患儿退热、止咳、抗菌、纠正水电解质紊乱等对症治疗。在此前提下,对照组予以利巴韦林注射液(齐鲁制药有限公司,国药准字H19993274)10 mg/(kg•d),配以5%葡萄糖溶液250 mL,静脉滴注,1次/天。观察组在上述基础上予以喜炎平注射液(江西青峰药业有限公司,国药准字Z20026249)5 mg/(kg•d),配以5%葡萄糖溶液250mL,静脉滴注,1次/天。两组患儿均治疗7 d。 1.3 观察指标:①比较两组的发热消失时间、咳嗽消失时间、鼻塞流涕消失时间。②根据《中药新药临床研究指导原则》[8]评价症候积分,包括发热、咳嗽、咽痛、鼻塞流涕,采用4级评分法评为0~3分,评分越高表明患儿病情越严重,以此为依据评价疗效:①无效:治疗后症状、体征均无明显改善,或病情加重,减分率<30%;②有效:症状、体征好转,减分率30%~69%;③显效:症状及体征明显改善,减分率70%~94%;④治愈:临床症状、体征消失消失,减分率≥95%,减分率=(治疗前临床症状积分-治疗后临床症状积分)/治疗前临床症状积分×100%,治疗有效率=(①+②+③)/51×100%。(3)统计不良反应发生情况,包括皮疹、恶心呕吐、白细胞减少。 1.4 统计学方法:将102例小儿上呼吸道感染患儿的临床数据输入SPSS23.0运行处理,以χ2检验疗效等无序分类资料(%、n),以t检验肺功能指标等数值变量资料( ),P<0.05,提示有差异。

友情链接